公开(公告)号：US11731943B2

公开(公告)日：2023-08-22

申请号：US17177356

申请日：2021-02-17

Applicant: Genentech, Inc.

Inventor： James John Crawford ,  Mark Zak ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  F. Anthony Romero ,  Paul Gibbons ,  Guiling Zhao ,  Gregory Hamilton ,  Simon Charles Goodacre

IPC: C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: Compounds of Formula (I):




and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20210179564A1

公开(公告)日：2021-06-17

申请号：US17177356

申请日：2021-02-17

Applicant: Genentech, Inc.

Inventor： James John Crawford ,  Mark Zak ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  F. Anthony Romero ,  Paul Gibbons ,  Guiling Zhao ,  Gregory Hamilton ,  Simon Charles Goodacre

IPC: C07D231/40 ,  C07D401/14 ,  C07D401/04 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D409/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US10968203B2

公开(公告)日：2021-04-06

申请号：US15989008

申请日：2018-05-24

Applicant: Genentech, Inc. ,  The Regents of the University of California

Inventor： Marie-Gabrielle Braun ,  Paul Gibbons ,  Wendy Lee ,  Cuong Ly ,  Joachim Rudolph ,  Jacob Schwarz ,  Avi Ashkenazi ,  Leo Fu ,  Tommy Lai ,  Fei Wang ,  Ramsay Beveridge ,  Liang Zhao

IPC: A61K31/506 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P35/00

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20190071404A1

公开(公告)日：2019-03-07

申请号：US16181228

申请日：2018-11-05

Applicant: Genentech, Inc.

Inventor： James John Crawford ,  Mark Zak ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  F. Anthony Romero ,  Paul Gibbons ,  Guiling Zhao ,  Gregory Hamilton ,  Simon Charles Goodacre

IPC: C07D231/40 ,  C07D401/04 ,  C07D405/04 ,  C07D403/08 ,  C07D409/14 ,  C07D401/14 ,  C07D405/12

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US10189836B2

公开(公告)日：2019-01-29

申请号：US16009596

申请日：2018-06-15

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Rongbao Hua ,  Terry Kellar ,  Wei Li ,  Paul Gibbons ,  Mark Edward Zak

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20180354959A1

公开(公告)日：2018-12-13

申请号：US16104347

申请日：2018-08-17

Applicant: Genentech, Inc.

Inventor： Mark Zak ,  Terry Kellar ,  Paul Gibbons

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds of Formula (I): salts thereof and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20180265497A1

公开(公告)日：2018-09-20

申请号：US15989008

申请日：2018-05-24

Applicant: Genentech, Inc. ,  The Regents of the University of California

Inventor： Marie-Gabrielle Braun ,  Paul Gibbons ,  Wendy Lee ,  Cuong Ly ,  Joachim Rudolph ,  Jacob Schwarz ,  Avi Ashkenazi ,  Leo Fu ,  Tommy Lai ,  Fei Wang ,  Ramsay Beveridge ,  Liang Zhao

IPC: C07D401/14 ,  A61K31/506 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  A61K45/06

CPC classification number: C07D401/14 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.